Next Article in Journal
MicroRNAs Associated with Von Hippel–Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review
Next Article in Special Issue
Deregulation of Frizzled Receptors in Hepatocellular Carcinoma
Previous Article in Journal
Argan Oil as an Effective Nutri-Therapeutic Agent in Metabolic Syndrome: A Preclinical Study
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(11), 2494;

Proteinase-Activated Receptor 2 May Drive Cancer Progression by Facilitating TGF-β Signaling

First Department of Medicine, University Hospital Schleswig-Holstein, D-23538 Lübeck, Germany
Department of General and Thoracic Surgery, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany
Department of General Pharmacology, Institute of Pharmacology, University Medicine Greifswald, D-17487 Greifswald, Germany
Department of General, Visceral and Vascular Surgery, Jena University Hospital, D-07747 Jena, Germany
Author to whom correspondence should be addressed.
Received: 6 November 2017 / Revised: 16 November 2017 / Accepted: 20 November 2017 / Published: 22 November 2017
(This article belongs to the Special Issue Cancer-Driver G Protein-Coupled Receptors as Therapeutic Targets)
Full-Text   |   PDF [890 KB, uploaded 22 November 2017]   |  


The G protein-coupled receptor proteinase-activated receptor 2 (PAR2) has been implicated in various aspects of cellular physiology including inflammation, obesity and cancer. In cancer, it usually acts as a driver of cancer progression in various tumor types by promoting invasion and metastasis in response to activation by serine proteinases. Recently, we discovered another mode through which PAR2 may enhance tumorigenesis: crosstalk with transforming growth factor-β (TGF-β) signaling to promote TGF-β1-induced cell migration/invasion and invasion-associated gene expression in ductal pancreatic adenocarcinoma (PDAC) cells. In this chapter, we review what is known about the cellular TGF-β responses and signaling pathways affected by PAR2 expression, the signaling activities of PAR2 required for promoting TGF-β signaling, and the potential molecular mechanism(s) that underlie(s) the TGF-β signaling–promoting effect. Since PAR2 is activated through various serine proteinases and biased agonists, it may couple TGF-β signaling to a diverse range of other physiological processes that may or may not predispose cells to cancer development such as local inflammation, systemic coagulation and pathogen infection. View Full-Text
Keywords: pancreatic carcinoma; signaling; TGF-β; ALK5; PAR2; serine proteinases pancreatic carcinoma; signaling; TGF-β; ALK5; PAR2; serine proteinases

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Ungefroren, H.; Witte, D.; Rauch, B.H.; Settmacher, U.; Lehnert, H.; Gieseler, F.; Kaufmann, R. Proteinase-Activated Receptor 2 May Drive Cancer Progression by Facilitating TGF-β Signaling. Int. J. Mol. Sci. 2017, 18, 2494.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top